NeoGenomics (NASDAQ:NEO) Price Target Raised to $14.00 at TD Cowen

NeoGenomics (NASDAQ:NEO) had its price target lifted by TD Cowen from $13.00 to $14.00 in a research note issued to investors on Wednesday,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

Other analysts have also issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of NeoGenomics in a research report on Friday, March 27th. Piper Sandler upped their price target on shares of NeoGenomics from $12.00 to $13.00 and gave the company an “overweight” rating in a research report on Tuesday, February 24th. William Blair restated a “market perform” rating on shares of NeoGenomics in a research report on Monday, March 16th. Needham & Company LLC upped their price target on shares of NeoGenomics from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Finally, Benchmark upgraded shares of NeoGenomics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Wednesday. Six analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $13.86.

NeoGenomics Stock Down 0.7%

Shares of NASDAQ:NEO opened at $8.96 on Wednesday. NeoGenomics has a 52-week low of $4.72 and a 52-week high of $13.74. The firm has a fifty day moving average of $8.48 and a 200 day moving average of $10.44. The firm has a market capitalization of $1.17 billion, a PE ratio of -10.67 and a beta of 1.72. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.94 and a current ratio of 4.26.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, April 28th. The medical research company reported $0.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.01. NeoGenomics had a negative net margin of 14.85% and a negative return on equity of 3.10%. The company had revenue of $186.67 million during the quarter, compared to analyst estimates of $184.53 million. The firm’s revenue for the quarter was up 11.3% compared to the same quarter last year. As a group, research analysts anticipate that NeoGenomics will post -0.17 EPS for the current fiscal year.

Hedge Funds Weigh In On NeoGenomics

A number of institutional investors have recently bought and sold shares of NEO. First Light Asset Management LLC raised its stake in NeoGenomics by 45.0% in the third quarter. First Light Asset Management LLC now owns 9,927,269 shares of the medical research company’s stock worth $76,639,000 after buying an additional 3,080,837 shares in the last quarter. Loomis Sayles & Co. L P bought a new position in NeoGenomics in the fourth quarter worth about $19,182,000. American Capital Management Inc. increased its stake in shares of NeoGenomics by 120.9% during the third quarter. American Capital Management Inc. now owns 2,345,263 shares of the medical research company’s stock valued at $18,105,000 after purchasing an additional 1,283,390 shares in the last quarter. Aberdeen Group plc increased its stake in shares of NeoGenomics by 127.1% during the fourth quarter. Aberdeen Group plc now owns 1,798,939 shares of the medical research company’s stock valued at $21,156,000 after purchasing an additional 1,006,676 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. increased its stake in shares of NeoGenomics by 69.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,218,727 shares of the medical research company’s stock valued at $26,093,000 after purchasing an additional 912,788 shares in the last quarter. 98.50% of the stock is owned by institutional investors.

More NeoGenomics News

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: Analyst upgrades: Leerink Partners upgraded NEO to “outperform” and raised its price target to $25 (from $12), implying large upside and signaling increased confidence in growth prospects. The Fly / Benzinga The Fly
• Positive Sentiment: TD Cowen raised its price target to $14 and placed a “buy” rating on NEO, providing additional analyst support that may attract buyers. Benzinga
• Positive Sentiment: Q1 results: Revenue of $186.7M beat the $184.5M consensus and revenue grew ~11.3% year-over-year; GAAP EPS matched the $0.01 consensus — signs of top-line momentum. MarketBeat earnings summary Press Release
• Neutral Sentiment: FY2026 revenue guidance was updated to roughly $797M–$803M, essentially in line with street expectations — supportive but not a clear beat; the company did not provide a clear EPS target in the release, leaving profitability outlook unclear. Slide Deck
• Neutral Sentiment: Management commentary and the Q1 earnings call transcript/slides are available for deeper detail on volume trends and margin drivers — useful for investors assessing sustainability of revenue growth. Earnings Call Transcript Presentation
• Negative Sentiment: Profitability remains a concern: NEO posted a negative net margin (~-14.9%) and negative ROE, and analysts still model negative full-year EPS — factors that limit valuation multiple expansion until margins improve. MarketBeat
• Negative Sentiment: Heavy intraday trading volume (well above average) and the lack of a clear EPS outlook likely prompted short-term selling/uncertainty despite bullish analyst headlines, contributing to the share decline today. Investing.com

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.